학술논문
Correction to: RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (Annals of Hematology, (2023), 102, 7, (1773-1787), 10.1007/s00277-023-05196-4)
Document Type
Erratum
Author
Source
In: Annals of Hematology . (Annals of Hematology, September 2023, 102(9):2643-2644)
Subject
Language
English
ISSN
14320584
09395555
09395555